Synbiotic loaded chitosan-Ca-alginate microparticles reduces inflammation in the TNBS model of rat colitis
Journal
International Journal of Pharmaceutics
Date Issued
2017
Author(s)
Tanja Petreska Ivanovska
Zoran Zhivikj,
Ivica Gjurovski
Lidija Petrushevska-Tozia
Abstract
New therapeutic strategies against inflammatory bowel disease (IBD) consider the usage of probiotics,
prebiotics and synbiotics as beneficial for the intestinal microbial balance. Limitations of such an
approach are addressed into difference in survival, persistence, colonization and variable effects among
different probiotic strains, lack in understanding of probiotic mechanisms of action, as well the complex
etiology of IBD. The anti-inflammatory activity of Lactobacillus casei 01 (L. casei 01) was assessed in
trinitrobenzenesulphonic (TNBS) acid model of rat colitis when the probiotic was used alone and/or in
combination with oligofructose-enriched inulin (Synergy 1), and as synbiotic (L. casei 01 + Synergy 1)
loaded chitosan-Ca-alginate microparticles; all suspended in ayran. The results from the probiotic/
synbiotic treatments (8.5–8.9 log CFU g 1 L. casei 01 and 1.5% Synergy 1) have shown reduction in the
colonic damage and increased lactobacilli counts in feces. Lactobacilli translocation to sterile extra-
intestinal organs demonstrated acceptable safety of the probiotic strain used. The best effect at reducing
inflammation and lesions associated with a significant decline in myeloperoxidase (MPO) activity was
observed in rats that received synbiotic microparticles. This
finding suggests colon targeted delivery of
the probiotics/synbiotics, as an advantageous approach in prevention and treatment of IBD.
prebiotics and synbiotics as beneficial for the intestinal microbial balance. Limitations of such an
approach are addressed into difference in survival, persistence, colonization and variable effects among
different probiotic strains, lack in understanding of probiotic mechanisms of action, as well the complex
etiology of IBD. The anti-inflammatory activity of Lactobacillus casei 01 (L. casei 01) was assessed in
trinitrobenzenesulphonic (TNBS) acid model of rat colitis when the probiotic was used alone and/or in
combination with oligofructose-enriched inulin (Synergy 1), and as synbiotic (L. casei 01 + Synergy 1)
loaded chitosan-Ca-alginate microparticles; all suspended in ayran. The results from the probiotic/
synbiotic treatments (8.5–8.9 log CFU g 1 L. casei 01 and 1.5% Synergy 1) have shown reduction in the
colonic damage and increased lactobacilli counts in feces. Lactobacilli translocation to sterile extra-
intestinal organs demonstrated acceptable safety of the probiotic strain used. The best effect at reducing
inflammation and lesions associated with a significant decline in myeloperoxidase (MPO) activity was
observed in rats that received synbiotic microparticles. This
finding suggests colon targeted delivery of
the probiotics/synbiotics, as an advantageous approach in prevention and treatment of IBD.